Head-to-head · free

Stevanato Group S.p.A. vs Teva Pharmaceutical Industries Limited

STVN vs TEVA — return on capital, cash generation, margins and balance sheet side by side.

STVN

1 / 4

measures where STVN leads

TEVA

3 / 4

measures where TEVA leads

A simple count of which company scores better on each measure — not a recommendation to buy or sell.

MeasureSTVNTEVA · FY2025
Revenue—$1.5B
Net income—$1.4B
Revenue growth (yearly, multi-year)—-44.6%
Free cash flow——
Free cash flow margin——
Net cash / (debt)——
ROIC7.7%—
Return on equity9.7%21.2%
Gross margin29.0%51.8%
Operating margin16.8%22.9%
Net debt / EBITDA1.13x4.19x

Figures are as reported by each company; latest fiscal year shown.

Where Stevanato Group S.p.A.'s cash went

Not reported yet.

Full STVN profile →

Where Teva Pharmaceutical Industries Limited's cash went (FY2025)

Capital spending
—
Buybacks
—
Dividends
—
Acquisitions
—
Net debt issued / (repaid)
—
Full TEVA profile →

Ask which business is stronger

"Which one reinvests at higher returns?" "Who carries more risk in its filings?" Get answers drawn straight from both companies' filings.

Compare them free

More comparisons